Menu
No results found.
6885
BRIM Biotechnology, Inc. – TPE
Weekly Share Price & Valuation Overview
Market Overview
Open
31.0000
Close
30.9000
High
31.3000
Low
30.8000
Trend
0.73680
BRIM Biotechnology, Inc.
Taiwan
• TPE - Taiwan Stock Exchange
• 6885
• Currency: TWD
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- TWD 4.08B
- Enterprise Value Operating value: market cap + total debt − cash.
- TWD 2.42B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- TWD 2.01M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- TWD 1.52M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- TWD 0.02
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -3.01
- Shares Outstanding
- 132.35M
- Float Shares
- 113.21M
- Implied Shares Outstanding
- 132.35M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-52.78%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
75.56%
- ROA Return on assets: net income ÷ total assets.
-
-11.44%
- ROE Return on equity: net income ÷ shareholder equity.
-
-21.45%
Growth
Growth rates are YoY unless labeled QoQ.
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
12.43%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.12
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.48
- Total Cash Cash and equivalents.
- TWD 1.66B
- Total Debt Short + long-term interest-bearing debt.
- TWD 9.02M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- TWD -1.65B
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 3
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
85.5%
Insiders
Shares held by company insiders (officers, directors).
22.5%
Institutions
Shares held by institutions (funds, pensions).
—
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
TWD -1.65B
-82368.0% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
As of: 2025-08-18 03:54
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.